Bia-Ceuticals has completed initials tests on the active compounds of its products in an inflammation model in human Keratinocytes (human skin cells).

​

Pre-clinical results show:

• 65-85% reduction of pro-inflammatory markers

• 45% improvement in skin-cell survival

• Proven Synergy – improved results in combination of our ingredients

 

The experiments were conducted at the laboratories of Dr. Barak Rotblat at Ben-Gurion University. Samples were sent for analysis to Eve Technologies, Canada .

 

First, we validated the model, determined the experimental conditions and the toxic and effective concentrations of our actives.

Subsequently, we tested our actives separately and in several combination and measured
cell-viability and leading inflammatory cytokines.